Express Scripts Holding Co (ESRX)

ESRX (NASDAQ:Health Services) EQUITY
$76.73
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | ESRX Avg Daily Volume: 3,791,500
Last Update: 12/06/16 - 4:00 PM EST
Volume: 0
YTD Performance: -12.22%
Open: $0.00
Previous Close: $76.73
52 Week Range: $64.46 - $89.00
Oustanding Shares: 616,621,000
Market Cap: 47,300,996,910
6-Month Chart
TheStreet Ratings Grade for ESRX
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 8 8 7
Moderate Buy 0 0 0 0
Hold 10 10 9 8
Moderate Sell 0 0 0 0
Strong Sell 1 1 2 2
Mean Rec. 2.23 2.23 2.33 2.37
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 18.18
Price Earnings Comparisons:
ESRX Sector Avg. S&P 500
18.18 18.20 0.00
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
5.51% -11.45% 14.61%
GROWTH 12 Mo 3 Yr CAGR
Revenue 0.90 0.10 0.03
Net Income 22.80 0.80 0.22
EPS 34.80 1.00 0.26
Earnings for ESRX:
EBITDA 6.70B
Revenue 101.75B
Average Earnings Estimates
Qtr (12/16) Qtr (03/17) FY (12/16) FY (12/17)
Average Estimate $1.87 $1.36 $6.39 $6.93
Number of Analysts 14 8 15 15
High Estimate $1.88 $1.39 $6.40 $7.14
Low Estimate $1.85 $1.33 $6.36 $6.75
Prior Year $1.56 $1.22 $5.53 $6.39
Growth Rate (Year over Year) 19.64% 11.37% 15.52% 8.46%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands

Why I'm Sticking With Biotech Real Money Pro($)

They offer a nice shelter for the headwinds now hitting equities.
Its hepatitis C drug will dominate the market.

Gilead Is a Buying Opportunity Real Money Pro($)

Its hepatitis C drug is better; the stock trades at a discount.
Here's the best way to play them.
Stocks that do well when the economy rises are shining.

In Defense of Gilead Sciences Real Money Pro($)

It has a great long-term future.
It might be good for consumers, but not for the stock.
Bearish
Sep 11, 2014 | 6:50 AM EDT
ESRX was downgraded from Buy to Neutral, Goldman Sachs said. $75 price target. Core business is facing fading growth drivers.

Stick With What Is Working Real Money Pro($)

Here are a few stocks I have made solid calls on recently that have moved up.
Bearish
Jul 30, 2014 | 8:16 AM EDT
ESRX price target lowered from $86 to $80, Jefferies said. Buy rating. Risk of incremental contract turnover.

Columnist Conversations

We bought some calls yesterday and rolled up.  This chart is fantastic, I'll have that out for everyone o...
Today I'll be talking credit spreads and specific trading strategies after the close today.  This will be...
Market slightly up at midday across the major indices.  Oil drifting back down to $50 a barrel as some eu...
The new Johnson Controls (JCI) had its introductory investor day yesterday in NYC, and laid out the structure,...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.